Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.

Abstract

Rationale: Advanced nasopharyngeal carcinoma (NPC) is an aggressive disease with no targeted therapies and poor outcomes. New innovative targets are urgently needed. KLF4 has been extensively studied in the context of tumors, and current data suggest that it can act as either a tissue-specific tumor-inhibiting or a tumor-promoting gene. Here, we found that KLF4 played as a tumor-promoting gene in NPC, and could be mediated by PLK1. Methods: Tissue immunohistochemistry (IHC) assay was performed to identify the role of KLF4 in NPC. Global gene expression experiments were performed to explore the molecular mechanisms underlying KLF4-dependent tumorigenesis. Small-molecule kinase inhibitor screening was performed to identify potential upstream kinases of KLF4. The pharmacologic activity of polo-like kinase inhibitor volasertib (BI6727) in vitro and in vivo was determined. Result: Our investigation showed that high expression of KLF4 was correlated with poor prognosis in NPC. Moreover, genome-wide profiling revealed that KLF4 directly activated oncogenic programmes, including gene sets associated with KRAS, VEGF, and MYC signalling. We further found that inhibition of polo-like kinase 1 could downregulate the expression of KLF4 and that PLK1 directly phosphorylated KLF4 at Ser234. Notably, phosphorylation of KLF4 by PLK1 caused the recruitment and binding of the E3 ligase TRAF6, which resulted in KLF4 K32 K63-linked ubiquitination and stabilization. Moreover, KLF4 could enhance TRAF6 expression at the transcriptional level, thus initiating a KLF4-TRAF6 feed-forward loop. Treatment with the PLK1 inhibitor volasertib (BI6727) significantly inhibited tumor growth in nude mice. Conclusion: Our study unveiled a new PLK1-TRAF6-KLF4 feed-forward loop. The resulting increase in KLF4 ubiquitination leads to stabilization and upregulation of KLF4, which leads to tumorigenesis in NPC. These results expand our understanding of the role of KLF4 in NPC and validate PLK1 inhibitors as potential therapeutic agents for NPC, especially cancer patients with KLF4 overexpression.

• Authors: Jia Mai, Zhuo-Yan Zhong, Gui-Fang Guo, Xiu-Xing Chen, Yan-Qun Xiang, Xuan Li, Hai-Liang Zhang, Yu-Hong Chen, Xue-Lian Xu, Rui-Yan Wu, Yan Yu, Zhi-Ling Li, Xiao-Dan Peng, Yun Huang, Li-Huan Zhou, Gong-Kan Feng, Xiang Guo, Rong Deng, Xiao-Feng Zhu
• Journal: Theranostics (Theranostics) Vol. 9 Issue 12 Pg. 3541-3554 ( 2019) ISSN: 1838-7640 [Electronic] Australia
• PMID: 31281496 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cell Cycle Proteins
• KLF4 protein, human
• Klf4 protein, mouse
• Kruppel-Like Factor 4
• Kruppel-Like Transcription Factors
• Proto-Oncogene Proteins
• Protein Serine-Threonine Kinases

Topics

• Animals
• Carcinogenesis
• Cell Cycle Proteins (metabolism)
• Cell Line
• Disease Models, Animal
• Gene Expression Profiling
• Humans
• Immunohistochemistry
• Kruppel-Like Factor 4
• Kruppel-Like Transcription Factors (metabolism)
• Mice, Nude
• Models, Biological
• Nasopharyngeal Carcinoma (pathology, physiopathology)
• Nasopharyngeal Neoplasms (pathology, physiopathology)
• Neoplasm Transplantation
• Phosphorylation
• Protein Processing, Post-Translational
• Protein Serine-Threonine Kinases (metabolism)
• Proto-Oncogene Proteins (metabolism)
• Transplantation, Heterologous
• Tumor Stem Cell Assay
• Polo-Like Kinase 1